Literature DB >> 8547659

Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2.

M Höglund1, B Johansson, J Pedersen-Bjergaard, P Marynen, F Mitelman.   

Abstract

Twenty patients with hematologic malignancies with 12p abnormalities were investigated by fluorescence in situ hybridization (FISH) using probes mapped to specific regions in 12p. The initial analysis using the YAC 964c10 (D12S736) revealed that all four cases with cytogenetically identified del(12p) had lost one copy of this YAC and that submicroscopic deletions had occurred in 10 of the 16 neoplasms with other 12p abnormalities, ie, translocations, additions, and insertions. The deletions were partially mapped with cosmids localized to subregions of 12p. One copy of the gene for p27kip1 (KIP1), involved in cell cycle entrance, was found to be lost in all cases in which deletions could be detected by other probes and in one case with a translocation as the only detectable change. This implicates KIP1 as a possible tumor suppressor gene affected by del(12p). Four translocations with no apparent concomitant deletions were detected. All four breakpoints resulted in a split D12S736 signal. In two of these cases, we showed that TEL was disrupted as a result of a t(5;12)(q32-33;p12) and a t(12;22)(p12;q12), respectively. Two lymphoid neoplasm--one non-Hodgkin's lymphoma and one Burkitt's lymphoma--with 12p amplifications were detected. In both cases cyclin D2 (CCND2) was within the amplified region. Thus, cytogenetic abnormalities of 12p in hematologic malignancies result in at least three different molecular changes: deletions of KIP1, amplifications of CCND2, and structural rearrangements of TEL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8547659

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  High-level DNA amplifications are common genetic aberrations in B-cell neoplasms.

Authors:  C A Werner; H Döhner; S Joos; L H Trümper; M Baudis; T F Barth; G Ott; P Möller; P Lichter; M Bentz
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Defining ploidy-specific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines.

Authors:  Grace Ng; Jingxiang Huang; Ian Roberts; Nicholas Coleman
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

3.  Molecular cytogenetic characterization of an ins(4;X) occurring as the sole abnormality in an aggressive, poorly differentiated soft tissue sarcoma.

Authors:  Cecilia Surace; Clelia Tiziana Storlazzi; Jacob Engellau; Henryk A Domanski; Pelle Gustafson; Ioannis Panagopoulos; Pietro D'Addabbo; Mariano Rocchi; Nils Mandahl; Fredrik Mertens
Journal:  Virchows Arch       Date:  2005-08-26       Impact factor: 4.064

Review 4.  Molecular pathogenesis of MDS.

Authors:  Hisamaru Hirai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter.

Authors:  S Fears; M Gavin; D E Zhang; C Hetherington; Y Ben-David; J D Rowley; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands.

Authors:  Carmo Martins; Branca Cavaco; Giovanni Tonon; Frederic J Kaye; Jorge Soares; Isabel Fonseca
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

7.  Aberrant DNA methylation of cyclin D2 and p27 genes in rodent pituitary tumor cell lines correlates with specific gene expression.

Authors:  X Qian; L Jin; R V Lloyd
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

8.  Transcriptome Analysis Showed a Differential Signature between Invasive and Non-invasive Corticotrophinomas.

Authors:  Leonardo Jose Tadeu de Araújo; Antonio Marcondes Lerario; Margaret de Castro; Clarissa Silva Martins; Marcello Delano Bronstein; Marcio Carlos Machado; Ericka Barbosa Trarbach; Maria Candida Barisson Villares Fragoso
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-22       Impact factor: 5.555

Review 9.  Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Authors:  Sunil K Joshi; Monika A Davare; Brian J Druker; Cristina E Tognon
Journal:  Leukemia       Date:  2019-09-24       Impact factor: 11.528

10.  Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target.

Authors:  Chin-Sheng Hung; Sheng-Chao Wang; Yi-Ting Yen; Tzong-Huei Lee; Wu-Che Wen; Ruo-Kai Lin
Journal:  Int J Mol Sci       Date:  2018-10-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.